The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.
 
Amir Goldkorn
Research Funding - Menarini Silicon Biosystems; RareCyte; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - I am listed as a co-inventor on a patent held jointly by USC and Caltech for a microfilter we developed for capturing live circulating tumor cells from blood.
 
Catherine Tangen
No Relationships to Disclose
 
Melissa Plets
No Relationships to Disclose
 
Daniel Bsteh
No Relationships to Disclose
 
Tong Xu
No Relationships to Disclose
 
Jacek K. Pinski
Stock and Other Ownership Interests - Cell BT
Consulting or Advisory Role - Bayer
Speakers' Bureau - AstraZeneca; Bayer; Dendreon; Myovant Sciences; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Dendreon; Myovant Sciences; Pfizer
 
Sue Ingles
No Relationships to Disclose
 
Timothy Junius Triche
Patents, Royalties, Other Intellectual Property - I have created and patented through Children's Hospital Los Angeles targeted nanoparticle small molecule (e.g., irinotecan, doxorubicin) delivery technology for the treatment of cancer. I also have a provisional patent filed for similar nanoparticle techn
 
Gary R. MacVicar
No Relationships to Disclose
 
Daniel A. Vaena
Honoraria - HMP; OncLive; OneOncology
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Immunomedics; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Exelixis (Inst); Merck (Inst); OBI Pharma (Inst); Roche/Genentech (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Tempus
 
Anthony W. Crispino
Consulting or Advisory Role - Pfizer
 
David James McConkey
Honoraria - H3 Biomedicine; Janssen Oncology
 
Primo N Lara
Research Funding - Janssen Biotech (Inst); Taiho Pharmaceutical (Inst)
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; AstraZeneca; AstraZeneca; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Precisca; Targeted Oncology; UroToday
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Pfizer; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
David I. Quinn
Employment - Abbvie
Honoraria - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Eisai; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Tanya B. Dorff
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bayer; Exelixis; Janssen Oncology; Pfizer; Sanofi/Aventis; Seagen
Research Funding - Pfizer (Inst)
 
Ian Thompson
Leadership - H-E-B (grocery store chain)
Consulting or Advisory Role - Magforce
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)